Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Drug discovery and development solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, pain, metabolic diseases, oncology, inflammation, respiratory and infectious diseases. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.
Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease.
Evotec is built on integrated drug discovery and development know-how of over 20 years and is a leading player in the drug discovery and integrated development field. The Company’s headquarters are located in Hamburg, Germany. Additional operating sites exist in Abingdon and Manchester, UK; Verona , Italy; Göttingen and Munich, Germany; South San Francisco, Branford and Princeton, Seattle, USA as well as Toulouse, France. Evotec has more than 3000 employees worldwide.
303B College Road East
Princeton, New Jersey 08540
Preclinical DevelopmentManufacturing and Analytical CharacterizationFormulation and Delivery